Recent content by Rrbatista

Research stopped in 2011 The FDA placed the program on clinical hold in 2011. The hold was prompted by the need to review certain adverse events, which included nosebleeds, gum bleeding and telangiectasias (small dilated blood vessels within the skin). There were no US patients on treatment or...